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Guochuan E. Tsai, and Hsien-Yuan LaneBackground: N-methyl-D-aspartate receptor (NMDAR)-mediated neurotransmission is vital for learning and memory. Hypofunction of
NMDAR has been reported to play a role in the pathophysiology of Alzheimer disease (AD), particularly in the early phase. Enhancing
NMDAR activation might be a novel treatment approach. One of the methods to enhance NMDAR activity is to raise the levels of NMDA
coagonists by blocking their metabolism. This study examined the efﬁcacy and safety of sodium benzoate, a D-amino acid oxidase
inhibitor, for the treatment of amnestic mild cognitive impairment and mild AD.
Methods: We conducted a randomized, double-blind, placebo-controlled trial in four major medical centers in Taiwan. Sixty patients with
amnestic mild cognitive impairment or mild AD were treated with 250–750 mg/day of sodium benzoate or placebo for 24 weeks. Alzheimer’s
Disease Assessment Scale-cognitive subscale (the primary outcome) and global function (assessed by Clinician Interview Based Impression of
Change plus Caregiver Input) were measured every 8 weeks. Additional cognition composite was measured at baseline and endpoint.
Results: Sodium benzoate produced a better improvement than placebo in Alzheimer’s Disease Assessment Scale-cognitive subscale
(p ¼ .0021, .0116, and .0031 at week 16, week 24, and endpoint, respectively), additional cognition composite (p ¼ .007 at endpoint) and
Clinician Interview Based Impression of Change plus Caregiver Input (p ¼ .015, .016, and .012 at week 16, week 24, and endpoint,
respectively). Sodium benzoate was well-tolerated without evident side-effects.
Conclusions: Sodium benzoate substantially improved cognitive and overall functions in patients with early-phase AD. The preliminary
results show promise for D-amino acid oxidase inhibition as a novel approach for early dementing processes.Key Words: Alzheimer disease, clinical trial, D-amino acids
oxidase (DAAO) inhibitor, mild cognitive impairment, N-methyl-
D-aspartate, sodium benzoate
The prevalence of dementia in elderly persons is increasingrapidly in the aging society, of which the deterioratingclinical course is a heavy burden to both the patients and
their family. Early detection and intervention of Alzheimer disease
(AD) is pivotal for the outcome (1). Mild cognitive impairment
(MCI), particularly amnestic mild cognitive impairment (aMCI), is a
risk factor and might be a prodromal stage of AD. The main-
stream treatment for mild and moderate AD is acetylcholine
esterase inhibitor (AChEI). However, its efﬁcacy and tolerability are
unsatisfactory. Furthermore, AChEI does not show convincing
efﬁcacy for MCI (2–4), implying that other mechanism(s) might
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http://dx.doi.org/10.1016/j.biopsych.2013.08.010Excessive glutamatergic neurotransmission, particularly through
the N-methyl-D-aspartate receptor (NMDAR), leads to neurotoxicity
(5,6), which is implicated in the pathophysiology of AD, especially in
the late phase. The NMDAR antagonists are developed for the
treatment of AD, on the basis of the hypothesis of NMDAR
overactivation (7). Memantine is an uncompetitive NMDAR partial
antagonist of low afﬁnity, which supposedly can block NMDAR
overactivation by preventing excessive inﬂux of calcium (8–10).
Memantine is approved as an antidementia medication for mod-
erate–severe AD (11); however, it has limited efﬁcacy at the early
phase, including MCI and mild AD (12). The NMDAR antagonists
such as MK-801 also induce apoptosis and neurodegeneration in
both in vitro and in vivo studies (13). Ketamine, another NMDAR
antagonist, impaired spatial learning and verbal information ability
in healthy humans in a double-blind, randomized, placebo-
controlled trial (14). These ﬁndings raise concern that NMDA
antagonist might impair cognition and memory in early AD.
Conversely, optimal NMDAR activation is pivotal for synaptic
plasticity (15), memory, and cognitive function (16). Attenuation
of NMDAR-mediated neurotransmission can result in loss of
neuronal plasticity and cognitive deﬁcits in the aging brain,
which might account for clinical deterioration and brain atrophy
(17). Age-related decrease in the density of NMDAR in cerebral
cortex and hippocampus was observed in humans (18). Earlier
studies also found a decrease of glycine-dependent radioligand
binding to the NMDAR in cerebral cortices from postmortem and
neurosurgical tissues in patients with AD (19,20). D-cycloserine, a
partial agonist at the glycine site of NMDAR, was reported in
some clinical studies to activate the NMDAR in brains of AD
patients (21) and improve their score on the cognitive subscale of
the Alzheimer’s Disease Assessment Scale (ADAS-cog) (22).
Recently, 1000 mg/day of sodium benzoate, an inhibitor ofBIOL PSYCHIATRY 2014;75:678–685
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neurocognitive function in patients with schizophrenia (23).
Because of the supporting evidence, we propose that NMDA-
enhancing agents might be beneﬁcial for the early declining
process of AD, due to their role in learning and memory as well as
neurogenesis and neuroplasticity.
There are several avenues to enhance NMDA activation. One
of them is inhibiting the activity of DAAO, a ﬂavoenzyme of
peroxisomes responsible for degrading D-serine and D-alanine
(24–26), and thereby raising levels of the D-amino acids that are
the neurotransmitters for the coagonist site of the NMDAR.
Recent data indicate that aging is related to reduced D-serine
levels and thereby impaired NMDAR transmission, and D-serine
treatment signiﬁcantly decreases the extent of neuron death,
suggesting that D-serine has neuroprotective effect against
apoptosis (27). In addition, neural stem cells from postnatal
mouse forebrain can synthesize D-serine and thereby stimulate
proliferation and neuronal differentiation of the stem cells (28).
Enhancing NMDAR through DAAO inhibition might be a safe
way to reduce nephrotoxicity of D-serine (29), particularly in the
elderly population. Sodium benzoate is a DAAO inhibitor. Benzoic
acid exists in many plants and is a natural constituent of food,
including milk products (30). Benzoic acid and its salts, including
sodium benzoate, which are generally recognized as safe, are also
food preservatives widely used in manufacturing fruit jelly, buffer,
soy-bean sauce, processed meat, and the like (31).
There are several other preclinical studies supporting the
central nervous system (CNS) effects of DAAO inhibitors, although
the memory effect was not examined (32–34). Sodium benzoate
is effective in NMDAR models such as pain relief (35,36) and
partially prevented cell death in glial cells (37). The CNS bioavail-
ability of benzoate is good (38). To test the hypothesis that DAAO
inhibition is beneﬁcial for the early phase of dementia, we
conducted this trial to examine the efﬁcacy and safety of sodium
benzoate in patients with aMCI or mild AD.Methods and Materials
Participants
Patients were recruited from the outpatient clinics at the
Department of Psychiatry and Department of Neurology, Kaohsiung
Chang Gung Memorial Hospital, Kaohsiung; Department of Psy-
chiatry, China Medical University Hospital, Taichung; Department of
Psychiatry, Taichung Veterans General Hospital, Taichung; and
Department of Neurology, Lin-Shin Hospital, Taichung, which are
four major medical centers in Taiwan. The study was approved by
the institutional review board at four sites and conducted in
accordance with the current revision of the Declaration of Helsinki.
Patients were evaluated by research psychiatrists and neurologists
after a thorough medical and neurological workup.
Patients were enrolled into this study if they: 1) satisﬁed
National Institute of Neurological and Communicative Disorders
and Stroke and the Alzheimer’s Disease and Related Disorders
Association (39) criteria for probable AD and had a Clinical
Dementia Rating (CDR) (40) score of 1 or criteria for an aMCI
(41) of a presumably degenerative nature deﬁned as subjective
memory complaint corroborated by an informant and insufﬁcient
global cognitive and functional impairment to meet National
Institute of Neurological and Communicative Disorders and
Stroke and the Alzheimer’s Disease and Related Disorders
Association criteria and had a CDR score of .5; 2) 50–90 years of
age; 3) were physically healthy and had all laboratory assessments(including urine/blood routine, biochemical tests, and electrocardio-
graph) within normal limits; 4) had a Mini-Mental State Examination
(42) score of 17–26; 5) had sufﬁcient education to communicate
effectively and were capable of completing the assessments of the
study; and 6) agreed to participate in the study and provided
informed consent. For patients who had already been on a regimen
of AChEI therapy, AChEI had to be continued for at least 3 months
before enrollment. The AChEI dose had to be kept unchanged
during the study duration. For patients who had not yet been on a
regimen of AChEI therapy, AChEI or other antidementia medication
was forbidden during the study duration.
Exclusion criteria included history of signiﬁcant cerebrovascular
disease; Hachinski Ischemic Score4; major neurological, psychiatric,
or medical conditions other than AD; substance (including alcohol)
abuse or dependence; delusion, hallucination, or delirium symptoms;
severe visual or hearing loss; and inability to follow protocol.
Study Design
All patients were randomly assigned to receive a 24-week
treatment of sodium benzoate or placebo in a double-blind
manner. Efﬁcacy and safety were evaluated at baseline and at the
ends of weeks 8, 16, and 24. Two hundred ﬁfty milligrams of
sodium benzoate or placebo were packed with identical capsules
provided in coded containers. The dose was started at 250–500 mg/
day (250 mg once or twice daily) in the ﬁrst 8 weeks, then increased
by 250–500 mg/day from the 9th week, and further increased by
another 250–500 mg/day from the 17th week of the study if
clinically indicated. On the basis of an earlier study in which sodium
benzoate given at the dose of 1000 mg/day improved a variety of
symptom domains and neurocognition in patients with chronic
schizophrenia without obvious side effects (23), we decided to
apply 250–750 mg/day, considering the older age of the subjects in
the present study. Patients were randomized in a cluster of six
subjects to receive sodium benzoate or placebo in a 1:1 ratio by an
independent investigational pharmacist.
Patients, caregivers, and investigators, except the investiga-
tional pharmacist, were all blind to the assignment. Patient
medical adherence and safety were closely monitored by care-
givers and research physicians, and pill-counting was monitored
by the study staff.
Assessments
The primary outcome was the Alzheimer’s Disease Assessment
Scale-cognitive subscale (ADAS-cog) (43) measured at weeks 0, 8,
16, and 24. The ADAS-cog is the most popular cognitive assess-
ment instrument used in AD clinical trials. It consists of 11 tasks,
including word recall, naming, commands, constructional praxis,
ideational praxis, orientation, word recognition, instructions
remembering, spoken language ability, word-ﬁnding difﬁculty,
and comprehension. Its scores range from 0 (best) to 70 (worst).
The secondary outcome measurements included the Clinician’s
Interview-Based Impression of Change plus Caregiver Input (CIBIC-
plus) (44) measured at weeks 8, 16, and 24 and the additional
cognition composite measured at baseline and endpoint.
The CIBIC-plus is a global assessment of change based on a
comprehensive, semi-structured interview that includes caregiver-
supplied information. It is a 7-point rating scale ranging from 1 to
7, where 1 represents markedly improved; 4 represents no
change; and 7 represents markedly worse.
The additional cognition composite was calculated by the
average of the T scores of speed of processing (Category Fluency),
working memory (Wechsler Memory Scale–Third Edition, Spatial
Span) (45), and verbal learning and memory tests (Wechsler Memorywww.sobp.org/journal
680 BIOL PSYCHIATRY 2014;75:678–685 C.-H. Lin et al.Scale–Third Edition, Word Listing) (45). The raw score of speed of
processing, working memory, and verbal learning and memory tests
was standardized to a T score with a mean of 50 and an SD of 10 for
making each test comparative. The additional cognition composite
was applied in combination with ADAS-cog to make the cognitive
assessment more thorough. Decrease in processing speed has been
found to be associated with aging (46,47). Working memory (48) and
verbal learning/memory (49) also decline in patients with AD.
Systemic side effects of treatments were evaluated by means
of physical and neurological examinations and laboratory tests
including CBC and biochemistry and reviewed by applying the
Udvalg for Kliniske Undersogelser Side-effects Rating Scale (50) at
baseline and weeks 8, 16, and 24.
Clinical ratings were performed by the research psychiatrists
and neurologists who were trained and experienced in the rating
scales. Inter-rater reliability was analyzed with the analysis of
variance test. Only raters reaching the intra-class correlation
coefﬁcients of $.90 during prestudy training were allowed to
rate the study patients. To maintain high inter-rater reliability and
to prevent rater drift, raters met at least once/quarter for training
and reliability retesting. To minimize inter-rater variability, each
individual patient was assessed by the same research psychiatrist
or neurologist throughout the trial.Sodium benzoate (n = 30) 
100% completed at least one follow-up
(n = 30) 
Assessed for eligibilit
3.3% discontinued (n = 1) 
0% adverse events (n = 0) 
3.6% non-adherence to protocol (n = 1) 
0% unsatisfactory therapeutic effect (n = 0) 
0% physical illnesses (n = 0) 
96.7% completed the trial 







Figure 1. Flow diagram and disposition of the two treatment groups.
www.sobp.org/journalData Analysis
Chi-square test (or Fisher’s exact test) was used to compare
differences of categorical variables and Student two-sample t test
(or Mann-Whitney U test if the distribution was not normal) was
used for continuous variables between two treatment groups. Mean
changes from baseline in repeated-measure assessments (ADAS-
cog) were assessed with the generalized estimating equation (GEE)
method with treatment, visit, and treatment-visit interaction as
ﬁxed effects and intercept as the only random effect and baseline
value as the covariance. The GEE analyses were performed with the
SAS/STAT (SAS Institute, Cary, North Carolina) “PROC GENMOD”
procedure with ﬁrst-order autoregressive working correlation struc-
ture with the marginal model instead of the mixed effect model.
Therapeutic effect sizes (Cohen’s d) were used to determine the
magnitude of improvement for the continuous variables (51)
resulting from sodium benzoate treatment compared with placebo.
Finally, all of the 60 randomized patients completed at least
one follow-up, and 50 (90%) of them completed the 24-week trial
(Figure 1). No imputation for the incomplete data was used for
the GEE analysis.
There were no baseline scores for the CIBIC-plus, because this is
scored as a judgment of change from baseline. Differences in CIBIC-
plus scores at weeks 8, 16, and 24 and endpoint between groupsPlacebo (n = 30) 
Excluded (n = 26) 
Not meeting inclusion criteria (n = 15) 
Declined to participate (n = 11) 
y (n = 86) 
3.3% completed the trial 
 = 25) 
00% completed at least one follow-up
 = 30) 
6.7% discontinued (n = 5) 
3.6% adverse events (n = 1) 
0% non-adherence to protocol (n = 0) 
7.1% unsatisfactory therapeutic effect (n = 2) 
7.1% physical illnesses (n = 2) 
= 60) 
Table 1. Baseline Demographic Characteristics of the Placebo or Sodium Benzoate Treatment Group
Treatment Groups
Benzoate (n ¼ 30) Placebo (n ¼ 30) p
Demographic Data
Female, n (%) 18 (60.0) 19 (63.3) 1.0a
Age, yrs, mean (SD) 70.7 (7.9) 69.7 (9.0) .64b
Age at illness onset, yrs, mean (SD) 69.8 (7.1) 68.5 (8.9) .54b
Illness duration, months, mean (SD) 14.2 (15.6) 13.6 (17.9) .47c
CDR at baseline, n (%) 1.0a
CDR .5 15 (50.0) 16 (53.3)
CDR 1 15 (50.0) 14 (46.7)
Education, yrs, mean (SD) 5.9 (4.7) 7.5 (5.2) .36c
BMI, mean (SD) 24.6 (4.1) 23.9 (3.4) .51b
Patients using AChEIs, n
Total 9 9 1.0a
Donepezil (dose, mean  SD) 7 (7.9  2.7) 5 (8.0  2.7) 1.0c
Rivastigmine (dose, mean  SD) 0 (.0  .0) 3 (7.5  2.6) NA
Galantamine (dose, mean  SD) 2 (16.0  .0) 1 (16.0  .0) 1.0c
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if the distribution was not normal).
Fisher’s exact test was used to compare differences in the
dropout rates between the two groups. Cohen’s w was applied forTable 2. Mean  SD Scores of Both Primary and Secondary Outcomes
Scale Benzoate, Mean  SD (n)
Primary Outcome
ADAS-cog
Baseline 15.6  7.6 (30)
Week 8 11.6  6.5 (30)
Week 16 9.8  6.2 (29)
Week 24 9.7  6.4 (28)
Endpoint 9.6  6.2 (30)
Drug
Week 8  drug
Week 16  drug
Week 24  drug
Endpoint  drug
Secondary Outcome
Additional cognition composite (T score)
Baseline 48.9  6.6 (26)
Endpoint 50.4  6.6 (26)
Difference 1.5  3.1 (26)
CIBIC-plus
Week 8 3.4  .5 (30)
Week 16 3.3  .6 (30)
Week 24 3.2  .7 (28)
Endpoint 3.2  .7 (30)
Results of measures of Alzheimer’s Disease Assessment Scale-cognitive sub
Impression of Change plus Caregiver Input (CIBIC-plus) over the 24-week tre
cognition composite, the composite test score of speed of processing, workin
aEstimate is the coefﬁcient of treatment–visit interaction term in the GE
covariance matrix was ﬁt to the within-patient repeated measures. The p valu
bIndependent t test.
cMann-Whitney U test was used, because the distribution of CIBIC-plus scodetermining the effect size of categorical variables (52). All data
were analyzed by IBM SPSS Statistics (version 18.0; SPSS, Chicago,
Illinois) or SAS version 9.3. All p values for clinical measures were
based on two-tailed tests with a signiﬁcance level of .05.Placebo, Mean  SD (n) Estimatea SEM Z p
15.0  7.3 (30)
11.7  8.5 (30) 2.8819 .9592 3.00 .0027
12.3  9.1 (26) 1.7582 1.2270 1.34 .1519
11.3  9.2 (25) 2.7456 1.1845 2.32 .0205
12.4  9.1 (30) 1.8067 1.1255 1.61 .1084
2.1860 2.2676 .96 .3351
1.0236 1.1491 .89 .3730
4.1835 1.3608 3.07 .0021
3.3543 1.3294 2.52 .0116
3.9648 1.3424 2.95 .0031
Cohen’s d t
51.2  8.4 (27) 1.111 .272b
49.6  8.7 (27) .404 .688b
1.6  4.8 (27) .7826 2.837 .007b
Cohen’s d Z p
3.5  .6 (30) .2441 .869 .385c
3.7  .7 (26) .6637 2.445 .015c
3.7  .7 (27) .6973 2.416 .016c
3.7  .8 (30) .7290 2.520 .012c
scale (ADAS-cog), additional cognitive tests, and Clinician Interview Based
atment with generalized estimating equations (GEE) method. Additional
g memory, and verbal learning, and memory.
E method multiple linear regression model. A ﬁrst-order autoregressive
es were based on two-tailed tests.
re was not normal.
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Table 3. Results of Measures of ADAS-cog Over 24-Week Treatment With GEE Method in Subgroups
Scale Benzoate Mean  SD (n) Placebo Mean  SD (n) Estimatea SEM Z p
CDR .5
Baseline 13.8  6.1 (15) 11.9  5.4 (16) Reference .3560
Week 8  drug 10.4  6.0 (15) 8.3  4.0 (16) .3213 .9690 .33 .7402
Week 16  drug 9.1  6.1 (15) 10.2  5.6 (15) 3.2694 1.9222 1.70 .0890
Week 24  drug 9.5  6.2 (14) 8.7  5.0 (14) 1.8480 1.7834 1.04 .3001
Endpoint  drug 9.2  6.1 (15) 9.8  5.9 (16) 2.3444 1.9664 1.19 .2332
CDR 1
Baseline 17.1  8.6 (15) 16.7  8.2 (14) Reference .8910
Week 8  drug 13.0  7.1 (15) 15.6  10.6 (14) 2.5727 2.0872 1.23 .2177
Week 16  drug 10.6  6.4 (14) 15.2  12.2 (11) 5.0788 2.0897 2.43 .0151
Week 24  drug 9.9  6.8 (14) 14.5  12.3 (11) 4.6262 2.2375 2.07 .0387
Endpoint  drug 10.0  6.6 (15) 15.4  11.3 (14) 5.4755 2.1031 2.60 .0092
Abbreviations as in Tables 1 and 2.
aEstimate is the coefﬁcient of treatment–visit interaction term in the GEE method multiple linear regression model. A ﬁrst-order autoregressive
covariance matrix was ﬁt to the within-patient repeated measures. The p values were based on two-tailed tests.
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Sixty patients were eligible and randomized (Figure 1). Demo-
graphic data, education level, age at illness onset, illness duration,
CDR, body mass index, and AChEI use at baseline were similar
between the benzoate group (n ¼ 30) and the placebo group (n ¼
30) (p  .05) (Table 1). The AChEI doses were within the therapeutic
range and similar between two groups (Table 1). Mean dose of
sodium benzoate at weeks 8, 16, and 24 were 275.0  76.3 mg/day,
525.0  100.6 mg/day, and 716.7  182.6 mg/day, respectively.
Outcome Measures
The mean  SD scores of both primary and secondary
outcomes—including ADAS-cog, additional cognition composite,
and CIBIC-plus—of the two groups of patients are shown in
Table 2. At week 0 (baseline), there were no signiﬁcant differences
between the two groups in ADAS-cog and additional cognition
composite (p ¼ .75 and p ¼ .27, respectively).
For the primary outcome, sodium benzoate produced greater
improvement in ADAS-cog score than the placebo therapy
throughout the study (mean differences from baseline were 3.8,
5.4, 5.9, and 5.9 in the benzoate group and 2.4, 1.7, 2.7, and 1.7 in
the placebo group, at weeks 8, 16, 24, and endpoint; p ¼ .3730,
p ¼ .0021, p ¼ .0116, and p ¼ .0031, respectively), with effect size
of .86 at the end of the study (Table 2). The results were similar
when the baseline ADAS-cog score was controlled in the GEE
model (Table S1 in Supplement 1).Table 4. Results of Measures of Additional Cognition Composite Over
24-Week Treatment with Independent t Test in Subgroups
Scale
Benzoate
Mean  SD (n)
Placebo
Mean  SD (n) Cohen’s d t p
CDR .5
Baseline 49.0  6.9 (14) 52.8  7.6 (15) 1.395 .174
Endpoint 50.5  7.1 (14) 50.8  8.5 (15) .108 .915
Difference 1.5  3.5 (14) 1.9  5.8 (15) .7098 1.939 .063
CDR 1
Baseline 48.8  6.6 (12) 49.3  9.3 (12) .150 .882
Endpoint 50.3  6.1 (12) 48.0  9.0 (12) .742 .466
Difference 1.6  2.8 (12) 1.3  3.5 (12) .9150 2.176 .041
The p values were based on two-tailed tests. Additional cognition
composite, the composite test score of speed of processing, working
memory, and verbal learning and memory.
CDR, Clinical Dementia Rating.
www.sobp.org/journalFor the secondary outcomes, sodium benzoate was better
than placebo in the additional cognition composite at endpoint
(p ¼ .007, effect size ¼ .78). Benzoate treatment also produced
greater improvement in CIBIC-plus score than placebo therapy at
week 16 (p ¼ .015), week 24 (p ¼ .016), and endpoint (p ¼ .012,
effect size ¼ .73 at endpoint) (Table 2).
The dropout rate (3.3%) of the sodium benzoate group tended
to be lower than that (16.7%) of the placebo group, yet
insigniﬁcantly (p ¼ .195).
For subgroup analysis, we further examined efﬁcacy of sodium
benzoate versus placebo in CDR .5 and CDR 1 subgroups. For ADAS-
cog, sodium benzoate produced greater improvement than pla-
cebo therapy at weeks 16 and 24 and endpoint (p ¼ .0151, p ¼
.0387, and p ¼ .0092, respectively) in the CDR 1 subgroup. However,
sodium benzoate was not superior to the placebo therapy in the
CDR .5 subgroup throughout the study (p  .05) (Table 3).
Sodium benzoate showed better efﬁcacy in the CDR 1
subgroup (p ¼ .041) and borderline signiﬁcance in the CDR .5
subgroup (p ¼ .063) in improving the additional cognition
composite (Table 4). For CIBIC-plus, sodium benzoate produced
greater improvement than placebo therapy at week 24 and
endpoint (p ¼ .040 and p ¼ .018, respectively) in the CDR 1
subgroup but not in the CDR .5 subgroup (Table 5).
Adverse Effects
Both sodium benzoate and placebo were well-tolerated. Only
one patient in the placebo group reported dizziness at week 16.
The side effect was mild and did not warrant medical treatment.
There was no reported side effect in the sodium benzoate group
assessed by the Udvalg for Kliniske Undersogelser Side-effects
Rating Scale at all visits. No dropout was due to side effect.
The routine blood cell count and chemistry were all within the
normal ranges and remained unchanged after treatment (data
not shown).Discussion
It is critical to identify and treat AD as early as possible, potentially
to arrest its progression (53). The current study is the ﬁrst to apply a
DAAO inhibitor, sodium benzoate herein, as a novel treatment for
the early stage of cognitive decline. The result showed that sodium
benzoate had better efﬁcacy than placebo in improving ADAS-cog
score, additional cognition composite (consisting of speed of
processing, working memory, and verbal learning and memory),
Table 5. Results of Clinical Measures of CIBIC-Plus Over 24-Week Treat-
ment with Mann-Whitney U Test in Subgroups
Scale
Benzoate
Mean  SD (n)
Placebo
Mean  SD (n) Cohen’s d Z p
CDR .5
Week 8 3.5  .5 (15) 3.4  .5 (16) .1771 .508 .611
Week 16 3.3  .5 (15) 3.7  .8 (15) .6042 1.720 .085
Week 24 3.3  .5 (14) 3.6  .6 (16) .4867 1.260 .208
Endpoint 3.3  .5 (15) 3.6  .6 (16) .4086 1.029 .303
CDR 1
Week 8 3.3  .5 (15) 3.6  .6 (14) .6697 1.719 .086
Week 16 3.2  .7 (15) 3.6  .5 (11) .7374 1.678 .093
Week 24 3.1  .8 (14) 3.8  .9 (11) .8805 2.052 .040
Endpoint 3.1  .8 (15) 3.9  .9 (14) .9494 2.370 .018
The p values were based on two-tailed tests. Mann-Whitney U test was
used, because the distribution of CIBIC-plus score was not normal.
CDR, Clinical Dementia Rating; CIBIC-plus, Clinician Interview Based
Impression of Change plus Caregiver Input.
C.-H. Lin et al. BIOL PSYCHIATRY 2014;75:678–685 683and global function in all subjects as a whole. Subgroup comparisons
found that benzoate was beneﬁcial for all outcome measures among
patients with mild AD. In the aMCI subgroup, sodium benzoate
showed borderline signiﬁcance in improving the cognition compo-
site, but not in ADAS-cog. This is probably due to small sample size
lacking the power to detect a smaller effect than mild AD. Moreover,
sodium benzoate also demonstrated favorable safety proﬁles.
Although NMDAR activity is essential for cognitive function, its
role in AD is still not fully understood. The NMDAR overactivation
by glutamate results in cell death. The excitotoxicity is one of the
theories of AD, particularly in the late stage (54). Memantine, a
low-afﬁnity, voltage-dependent uncompetitive NMDA antagonist,
has been used for the treatment of moderate–severe AD. The
current study suggests that NMDAR enhancement is beneﬁcial for
early and mild dementia. There is an age-related decrease of
glutamate content and synthesis in human cerebral cortex and
hippocampus (18,55), of which the most signiﬁcant and consis-
tent ﬁnding is decreased density of NMDAR in elderly persons
and in patients with AD (18). Lower levels of D-serine and higher
levels of L-serine in the serum were also observed in patients with
AD (56). Therefore, in addition to the cholinergic system,
dysfunction of NMDA neurotransmission might also play an
important role in the pathophysiology of AD.
With regard to the dosing strategy, sodium benzoate provided
better efﬁcacy than placebo at week 16 and week 24, with the
mean dose of 525 mg/day and 716 mg/day respectively, possibly
implying that sodium benzoate at 500–750 mg/day is more
effective than 250 mg/day. Another possibility is that longer sodium
benzoate treatment duration yields better treatment response.
Further studies comparing different doses of sodium benzoate
with a ﬁxed-dose design are required for ﬁnding the time to
response and the optimal dose for the treatment of mild AD or MCI.
The AChEIs are commonly used for the treatment of AD (57,58)
but not recommended for the treatment of MCI, due to weak
beneﬁcial effects and risk of side effects (59,60). The consensus
statement from the British Association for Psychopharmacology
concludes that neither AChEIs nor memantine is effective in
treating MCI (61). Other compounds commonly used for the
treatment of MCI, such as vitamin E (62), folic acid (63), omega-3
fatty acid (64), piracetam (65), and ginkgo biloba (66), also failed
to show convincing evidence for a cognitive enhancing effect.
Sodium benzoate is generally safe; however, its efﬁcacy for aMCIdid not reach statistical signiﬁcance in the current small-sized
study either, although it suggested a trend of improvement.
Although ADAS-cog is widely used in AD clinical trials, it might
be less sensitive for MCI (67). One of the strategies to improve the
detection of responsiveness for MCI is to add additional cognitive
tests. People with MCI have been found to be impaired in
neuropsychological functions (68) such as speed of processing
(69), working memory (70), and verbal learning and memory (71).
In the aMCI subgroup of the present study, sodium benzoate
showed borderline signiﬁcance in improving the additional
cognition composite, consisting of speed of processing, working
memory, and verbal learning/memory, but not in ADAS-cog
score. Our result echoes the suggestion that additional neuro-
psychological tests that are more sensitive to subtle deﬁcits
should also be applied in the trials for MCI.
In addition, sodium benzoate also did not improve CIBIC-plus
score in the aMCI subgroup. A possible explanation is a ceiling
effect that functional impairment is minimal in the MCI individ-
uals, thereby restricting the space for further improvement. More
sensitive and speciﬁc measurements for the function of MCI
individuals, such as Clinical Dementia Rating Sum of Boxes (72) or
Alzheimer’s disease Cooperative Study scale for ADL in MCI (73),
can be applied in the future studies for MCI.
This study is limited by its small sample size, which led to
underpowered results particularly in the subgroup analysis of
aMCI and a lack of MCI-speciﬁc functional assessments. Further-
more, whether the ﬁnding in Han Chinese can be extrapolated to
other populations is unclear. We have found that benzoate can
increase the brain mass by magnetic resonance imaging study
(74) and is beneﬁcial for neurocognitive function in patients with
schizophrenia (23). Biomarkers such as neurocognitive, cerebro-
spinal ﬂuid, and neuroimaging data are also important for future
studies to strengthen the methodology of detection.
Very high levels of DAAO are detected in the cerebellum of adult
brain, whereas the activity of DAAO is low in the forebrain, such as
prefrontal cortex and hippocampus, despite robust expression
(75,76). The cellular localization and function of DAAO are likely
different between forebrain and cerebellum: it is glial in the
cerebellum but mainly neuronal in the cerebral cortex. However,
the effect of DAAO inhibitors on forebrain D-serine level is
inconsistent. Most DAAO inhibitors can cause a measurable increase
in D-serine in the forebrain as observed in the cerebellum (77),
whereas some inhibitors might not. Nevertheless, cerebellum is
involved in cognition. Sodium benzoate might exert its procognitive
effects by not only cerebral but also cerebellar mechanism.
Despite the aforementioned limitations, this study suggests that
sodium benzoate, a DAAO inhibitor, is beneﬁcial for cognitive and
overall function in patients with early-phase AD. If the ﬁnding is
conﬁrmed in future larger-sized studies, this approach of applying
NMDA-enhancing agents for early AD will bring hope for the
growing aging population with cognitive decline. Because of the
ﬁndings that cognitive deﬁcits (the core symptoms of schizophre-
nia) can be improved by sodium benzoate in patients with
schizophrenia (23), the potential of NMDA-enhancing agents in
improving cognitive function for patients with other CNS disorders
or for general populations deserves further investigation.
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